Myriad Commercially Launches Precise MRD with Select Community Oncologists
Rhea-AI Summary
Myriad (NASDAQ: MYGN) launched the Precise MRD tumor-informed circulating tumor DNA (ctDNA) test on March 2, 2026, with a select group of community oncologists for patients with breast cancer.
The assay uses whole-genome sequencing to create personalized tests and enables ultrasensitive ctDNA detection down to one part per million. Myriad plans a broader U.S. commercial rollout later in 2026, with no limit on participating patients in the initial release.
Positive
- Commercial launch with select community oncologists announced March 2, 2026
- Ultrasensitive ctDNA detection down to one part per million
- Personalized assays built by whole-genome sequencing for each patient
Negative
- Initial roll-out limited to selected oncology practices, not yet nationwide
- No pricing, reimbursement, or coverage details disclosed in the announcement
Key Figures
Market Reality Check
Peers on Argus
MYGN fell 5.14% while peers were mixed: FLGT -19.42%, CDNA +1.13%, CSTL -1.00%, PSNL +5.23%, NEO -1.01%, pointing to a stock-specific reaction to the launch.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Oncology data update | Positive | +1.1% | ASCO-GU abstracts showing clinical performance for Precise MRD, Prolaris, MyRisk. |
| Feb 23 | Earnings and guidance | Neutral | +1.1% | Q4 and 2025 results with reiterated 2026 revenue and margin guidance. |
| Feb 19 | Prenatal test data | Positive | +0.2% | FirstGene analytical validation showing high sensitivity and specificity across components. |
| Feb 16 | Earnings call notice | Neutral | +0.2% | Announcement of timing for Q4 and full-year 2025 earnings release and call. |
| Jan 27 | MRD roadmap update | Positive | +1.9% | Plans for limited Precise MRD launch and strong ctDNA sensitivity data in studies. |
Recent news and earnings, including prior Precise MRD updates, generally saw modestly positive price reactions, making today’s decline a deviation from the recent pattern.
Over the past months, Myriad reported Q4 and full‑year 2025 results, reiterated 2026 guidance, and highlighted new launches like Precise MRD and FirstGene. Multiple news items, including MRD commercialization plans on Jan 27 and ASCO‑GU data on Feb 24, emphasized ultra‑sensitive ctDNA detection and broader oncology positioning. Those announcements saw small positive moves, whereas today’s commercial launch with select community oncologists comes alongside a notably negative price reaction, despite continuing the same MRD commercialization narrative.
Regulatory & Risk Context
An effective S-3 shelf dated Feb 24, 2026 allows Myriad Genetics to offer up to $200,000,000 of various securities over time for general corporate purposes, including operations, R&D, potential debt repayment, and acquisitions. No usage has been recorded yet under this shelf.
Market Pulse Summary
This announcement marks the commercial debut of Precise MRD with select community oncologists for breast cancer, following earlier disclosures on its ultra‑sensitive ctDNA detection down to 1 part per million. It continues Myriad’s strategy of building a comprehensive cancer diagnostics portfolio. Investors may track how quickly the limited rollout broadens, reimbursement dynamics, and future SEC filings under the existing $200,000,000 shelf to understand the balance between growth investment and potential dilution.
Key Terms
molecular residual disease medical
ctDNA medical
circulating tumor DNA medical
whole-genome sequencing medical
AI-generated analysis. Not financial advice.
Launch Represents Significant Step to Broader Commercialization
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer.
“The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low levels, the Precise MRD test will enable earlier insight and more informed treatment decisions,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. “This launch demonstrates the new Myriad’s ability to execute with discipline and deliver innovative diagnostics on a defined commercial timeline.”
The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a personalized assay for each patient, Precise MRD enables ultrasensitive detection of ctDNA down to one part per million.
"As a medical oncologist, I am excited about the advancements being made in our ability to detect, treat, and monitor cancer,” said Derrick S. Haslem, MD, ACMO of Specialty Care at Intermountain Health in Desert Region. “Precise MRD testing has emerged as a powerful tool in modern oncology, enabling physicians to detect cancer cells that persist after treatment but remain invisible to conventional imaging and microscopic examination.”
In this initial launch, the test will be available to community oncologists whose patients have been diagnosed with breast cancer. The initial roll-out will involve selected oncology practices, with no limit on the number of participating patients. Myriad is planning a broader commercial launch of the Precise MRD test across the U.S. later this year for patients with breast cancer.
“Precise MRD gives us greater visibility into whether treatment is working, which is especially important for a rural practice. A lot of my patients travel many miles to come to my office, so conducting multiple screening tests, like imaging, to determine if their cancer has spread can be physically difficult,” said Sucharu Prakash, MD, Director of Quality Services for Texas Oncology and Past President of Texas Society of Clinical Oncology. “The Precise MRD test represents an important component in determining – on a personalized basis – what and how many cancer treatments we should prescribe or order.”
About Precise MRD
The Precise MRD test provides molecular insights across the cancer care continuum. After diagnosis, the test can help clinicians determine if adjuvant treatment is needed, or if cancer has recurred. Should cancer metastasize in a patient, Precise MRD can provide molecular insights showing whether treatment is working or if a patient’s ctDNA is increasing.
For baseline tests, a personalized panel is developed based on a whole-genome sequencing profile of tumor tissue, and then the panel is used to measure the ctDNA level from an initial blood draw. For ongoing monitoring, the panel measures ctDNA levels from samples collected with a frequency based on where patients are in the treatment process.
Clinicians will receive an easy-to-read report that shows whether ctDNA was detected or not. If ctDNA is detected, the concentration of ctDNA is reported, which allows clinicians to see historical results of the patient’s ctDNA concentration over time.
Learn more at myriad.com/oncology/precise-mrd-test/.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the Precise MRD test will enable earlier insight and more informed treatment decisions and the Company is planning a broader commercial launch of the Precise MRD test across the U.S. later this year for patients with breast cancer. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What is Myriad's Precise MRD test (MYGN) and how sensitive is it?
When did Myriad (MYGN) commercially launch Precise MRD for breast cancer?
Which patients and physicians can access Precise MRD now from Myriad (MYGN)?
Will Precise MRD be available nationwide for MYGN shareholders to watch for?
How does Precise MRD help clinicians managing breast cancer patients, according to Myriad?
Does the Myriad (MYGN) announcement include pricing or reimbursement information for Precise MRD?
